Drug Trial Radar · NCT02090764
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
Last checked: Nov 19, 2026Latest source record: Aug 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
412
Actual
Start
Jun 2014
Primary completion
May 2015
Study completion May 2015
Sponsor
- Lead sponsor
- Ferrer Internacional S.A.Industry
- Sponsor type
- Industry
- First posted
- Mar 18, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is multicenter, randomised, placebo controlled, parallel, double blinded , superiority clinical study comparing ozenoxacin cream versus placebo, in patients with a clinical diagnosis of non-bullous or bullous impetigo.
Conditions
- Impetigo
Interventions
OzenoxacinDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical SuccessTime frame: Visit 3 (Day 6-7)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Caparra Internal Medicine Center
Rio Grande, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.